The cost–effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims. To determine the cost‐effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States, particularly its effect on the HIV epidemic. Design. We developed a dynamic model to capture the effects of adding buprenorphine maintenance to the current opiate dependence treatment system. We evaluated incremental costs, including all health‐care costs, and incremental effectiveness, measured as quality‐adjusted life years (QALYs) of survival. We considered communities with HIV prevalence among injection drug users of 5% and 40%. Because no price has been set in the United States for a dose of buprenorphine, we considered three prices per dose: $5, $15, and $30. Findings. If buprenorphine increases the number of individuals in maintenance treatment by 10%, but does not affect the number of individuals receiving methadone maintenance, the cost‐effectiveness ratios for buprenorphine maintenance therapy are less than $45 000 per QALY gained for all prices, in both the low‐prevalence and high‐prevalence communities. If the same number of individuals enter buprenorphine maintenance (10% of the number currently in methadone), but half are injection drug users newly entering maintenance and half are individuals who switched from methadone to buprenorphine, the cost‐effectiveness ratios in both communities are less than $45 000 per QALY gained for the $5 and $15 prices, and greater than $65 000 per QALY gained for the $30 price. Conclusions. At a price of $5 or less per dose, buprenorphine maintenance is cost‐effective under all scenarios we considered. At $15 per dose, it is cost‐effective if its adoption does not lead to a net decline in methadone use, or if a medium to high value is assigned to the years of life lived by injection drug users and those in maintenance therapy. At $30 per dose, buprenorphine will be cost‐effective only under the most optimistic modeling assumptions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“Abrupt discontinuation of buprenorphine leads to withdrawal syndrome that is only mild to moderate.(10,11) Also,”
BackgroundClinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
A Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence
Ling, W. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050035005 · Cited by 366
A meta‐analysis comparing buprenorphine to methadone for treatment of opiate dependence
Barnett, P. G., Rodgers, J. H., & Bloch, D. A. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9656834.x · Cited by 150
Self-citation
Cited by
Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 585
McCollister, K. E., & French, M. T. (2003) · Addiction · doi:10.1111/j.1360-0443.2003.00541.x · Cited by 114
Linas, B. P., Barter, D. M., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1313 · Cited by 101
Schackman, B. R., Leff, J. A., Polsky, D., Moore, B. A., & Fiellin, D. A. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1962-8 · Cited by 100
CHISHOLM, D., DORAN, C., SHIBUYA, K., & REHM, J. (2006) · Drug and Alcohol Review · doi:10.1080/09595230600944487 · Cited by 86
“[24] measured the cost-effectiveness of addiction treatment in terms of life-years gained or quality-adjusted lifeyears and demonstrated that MMT and BMT are costeffective treatment options under certain conditions.”
Background
Metadata
- Authors
- Barnett, P. G., Zaric, G. S., & Brandeau, M. L.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2001-09
- Volume
- 96
- Issue
- 9
- Pages
- 1267-1278
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W1984436733
- Cited by
- 129
- References
- 5
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The cost–effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. https://app.cochat.ai/papers/10.1046/j.1360-0443.2001.96912676.x
- The paper
- Barnett, P. G., Zaric, G. S., & Brandeau, M. L. (2001). The cost–effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. https://doi.org/10.1046/j.1360-0443.2001.96912676.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.